TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01442051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution
Description: A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
Study: NCT05088551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
Study: NCT01004510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
Study: NCT02527213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
Study: NCT01624272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).
Description: Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Pranayama breathing exercises
Description: Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
Study: NCT02112123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icariin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icariin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icariin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icariin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icariin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study: NCT00851305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscope (Pentax, Tokyo, Japan)
Description: A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopes (Pentax, Tokyo, Japan)
Description: Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
Study: NCT01524874

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 10,000 IU per Day for 12 Weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 10,000 IU per Day for 12 Weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 10,000 IU per Day for 12 Weeks
Study: NCT01924247

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Outpatient secondary prevention program
Description: The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard treatment by family physician
Description: Standard treatment by family physician.
Study: NCT00983996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium Tablets, 10 mg
Description: 10 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax Tablets, 10 mg
Description: 10 mg, single-dose fasting
Study: NCT01706757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: go-cart
Description: conducts exercises with the help of a go-cart
Study: NCT03032536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3778
Description: AL-3778 tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3778
Description: AL-3778 tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3778
Description: AL-3778 tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3778
Description: AL-3778 tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3778
Description: AL-3778 tablets or capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate once daily for 14 days
Study: NCT03227939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy（LSG）
Description: LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy（LSG）
Description: LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy
Description: UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
Study: NCT03285438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced dose of DOAC
Description: The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full dose of DOAC
Description: The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
Study: NCT03306277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
Study: NCT03858933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eBrainFit Platform
Description: Alpha/Theta regulation with eyes open

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eBrainFit Platform
Description: Amygdala regulation with eyes open
Study: NCT02878148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic imaging modalities for suspected renal colic
Description: All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol.
Study: NCT01929187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytonail

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl
Study: NCT02895802

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Verbal instructions with picture diagram
Description: verbal instructions and picture diagram

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Verbal instructions with video of ADSC
Description: Verbal instructions and watching video depicting ADSC

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: verbal instructions w. video of w/o DS
Description: verbal instructions and watching video depicting person without DS washing her hands

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: verbal instructions w. video w/DS
Description: verbal instructions and watching video depicting person with DS washing his hands
Study: NCT00592579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol
Description: 800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
Study: NCT02293928

Intervention type: PROCEDURE
Intervention: Hybrid coronary revascularization
Description: Hybrid coronary revascularization with standard double antiplatelet therapy
Study: NCT03877263

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vaginal swab for detection of STI
Description: After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vaginal swab for detection of STI
Description: After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups
Study: NCT01722136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Dosage
Description: Exercise dose of 8kcal/kg/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Dosage
Description: Exercise dose of 14kcal/kg/week
Study: NCT03666910

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometer
Description: detection of hearing problems

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometer
Description: detection of hearing problems

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometer
Description: detection of hearing problems
Study: NCT04118582

Intervention type: OTHER
Intervention: Body composition and resting metabolic rate analisys
Study: NCT04260373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SHR4640
Description: Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
Study: NCT02986555

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Existing Biofeedback
Description: Using relaxing assisted biofeedback approach

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback accompanied with virtual reality
Description: Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
Study: NCT04020796

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
Study: NCT03296956

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for appearance, taste
Study: NCT01939535

Intervention type: OTHER
Intervention: No intervention
Description: Evaluation of an imaging technique ic MRI
Study: NCT00728351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin + metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000 bid metformin
Study: NCT01694563

Intervention type: DEVICE
Group type: OTHER
Intervention: Synergy Ablation System
Description: Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~* Coronary Artery Bypass Grafting (CABG)~* Mitral valve repair or replacement~* Aortic valve repair or replacement~* Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria.
Study: NCT00687206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg plus HCT 25mg
Description: valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
Study: NCT03573544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-888
Description: For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-888
Description: For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globo H IHC Assay
Description: This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globo H IHC Assay
Description: This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
Study: NCT04542746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical technique
Description: After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical technique
Description: After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
Study: NCT04919785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
Study: NCT02270697

Intervention type: DEVICE
Intervention: Array
Description: Applications of oligonucleotide array in diagnosis.
Study: NCT00227370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valganciclovir
Description: valgan 900mg QD x 9 months post lung transplant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03056144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration therapy
Description: The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min \>5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant.
Study: NCT03332732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133
Description: β-lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5022
Description: Approved β-lactam antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5022
Description: Approved β-lactam antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5022
Description: Approved β-lactam antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5022
Description: Approved β-lactam antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Approved antibiotic and antiprotozoal medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (matching VNRX-5133 + VNRX-5022)
Study: NCT02291796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
Study: NCT01739647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study: NCT01670643

Intervention type: BEHAVIORAL
Intervention: Video camera magnifier
Description: reading with video camera magnifier